Kinase fusions identified in Ph-like ALL
| Kinase . | TKI . | Novel partners, n . | Partners to date, n . | Patient cases in current study, n . | 5′ Fusion partners in current study . |
|---|---|---|---|---|---|
| ABL1 | Dasatinib | 3 | 12 | 17 | CENPC,*ETV6, LSM14A,*NUP153,*NUP214, RANBP2, RCSD1, ZMIZ1 |
| ABL2 | Dasatinib | 0 | 3 | 4 | RCSD1, ZC3HAV1 |
| CSF1R | Dasatinib | 1 | 2 | 4 | SSBP2, TBL1XR1* |
| PDGFRB | Dasatinib | 1 | 6 | 15 | ATF7IP, EBF1, TNIP1, ZMYND8* |
| LYN | Dasatinib | 1 | 2 | 1 | GATAD2A* |
| JAK2 | JAK2 inhibitor | 3 | 14 | 14 | BCR, PAX5, PCM1, RFX3,*USP25,*ZNF274* |
| EPOR | JAK2 inhibitor | 0 | 2 | 11 | IGH |
| NTRK3 | TRK inhibitor | 0 | 1 | 1 | ETV6 |
| Kinase . | TKI . | Novel partners, n . | Partners to date, n . | Patient cases in current study, n . | 5′ Fusion partners in current study . |
|---|---|---|---|---|---|
| ABL1 | Dasatinib | 3 | 12 | 17 | CENPC,*ETV6, LSM14A,*NUP153,*NUP214, RANBP2, RCSD1, ZMIZ1 |
| ABL2 | Dasatinib | 0 | 3 | 4 | RCSD1, ZC3HAV1 |
| CSF1R | Dasatinib | 1 | 2 | 4 | SSBP2, TBL1XR1* |
| PDGFRB | Dasatinib | 1 | 6 | 15 | ATF7IP, EBF1, TNIP1, ZMYND8* |
| LYN | Dasatinib | 1 | 2 | 1 | GATAD2A* |
| JAK2 | JAK2 inhibitor | 3 | 14 | 14 | BCR, PAX5, PCM1, RFX3,*USP25,*ZNF274* |
| EPOR | JAK2 inhibitor | 0 | 2 | 11 | IGH |
| NTRK3 | TRK inhibitor | 0 | 1 | 1 | ETV6 |
Indicates new 5′ fusion partner identified.